AsherChanan-KhanMD

Oncology • Jacksonville, FL

Professor of Medicine, Mayo Clinic School of Medicine

Join to view full profile

Dr. Chanan-Khan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chanan-Khan's full profile

Already have an account?

Office
4500 San Pablo Rd S
Jacksonville, FL 32224
Phone+1 904-953-2000

Summary

Dr. Asher Chanan-Khan is an oncologist in Jacksonville, FL and is affiliated with Mayo Clinic Hospital in Florida. He received his medical degree from Allama Iqbal Medical College and has been in practice 24 years. He also speaks multiple languages, including Punjabi, Hindi, and Urdu. He specializes in hematologic oncology and is experienced in CLL, Waldenstrom Macroglobulinemia, hematologic oncology, and multiple myeloma.

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2000
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1998 - 1999
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1997 - 1998
Harlem Hospital CenterResidency, Internal Medicine, 1994 - 1997
Allama Iqbal Medical CollegeClass of 1993

Certifications & Licensure

FL State Medical License 2011 - 2026
NY State Medical License 2002 - 2023
NJ State Medical License 1998 - 2003
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Healthcare Heroes Jacksonville Business, 2016
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Buffalo Spree Magazine Castle Connolly, 2008, 2011
Join now to see all

Clinical Trials

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma Start of enrollment: 2004 Aug 01
Completed
Phase 2
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders Start of enrollment: 2005 Aug 01
Terminated
Phase 1
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2005 Apr 01
Completed
Phase 1
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia Start of enrollment: 2006 Dec 01
Completed
Phase 1
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Mar 01
Completed
Phase 2
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia Start of enrollment: 2015 Jul 09
Terminated
Phase 1, Phase 2
Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2010 Dec 01
Withdrawn
Phase 1
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia Start of enrollment: 2010 Dec 01
Withdrawn
Phase 2
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy Start of enrollment: 2016 Feb 08
Active, not recruiting
Phase 2
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma Start of enrollment: 2016 Apr 14
Completed
Phase 1
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia Start of enrollment: 2018 Jul 05
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.
Karan L Chohan, Rajiv K Pruthi, Saurabh Zanwar, Jonas Paludo, Ronald Go
Leukemia. 2024-11-01
1 citations
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation.
Karan Chohan, Jonas Paludo, Surendra Dasari, Patrizia Mondello, Joseph P Novak
Blood. 2024-09-19
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
Ricardo D Parrondo, Betsy R LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J Flott
Blood Cancer Journal. 2024-09-05

Abstracts/Posters

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (C...
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (C...
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sociodemographic and Clinical Characteristics Associated with PatientÍs Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes
Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS over 9 MonthsDecember 10th, 2024
Cellectar Biosciences : Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors (Form 8-K)June 25th, 2021
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of DirectorsJune 24th, 2021
Join now to see all